Mike Grey appointed Executive Chair of Theolytics' Board of Directors [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
OXFORD, England March 21, 2024 /PRNewswire/ -- Theolytics, a biotechnology company developing category changing cancer therapies in the form of oncolytic viruses, today announced the appointment of Michael (Mike) Grey succeeding Dr. Ken Powell , who is retiring from the Board having served as Chair since 2019. This appointment comes at a pivotal time for Theolytics as the Company advances its lead asset - THEO-260 - into clinical trials in ovarian cancer this year. THEO-260 is an oncolytic adenovirus that has demonstrated compelling efficacy in preclinical studies, selected to be effective in stromal-rich solid tumors, combined with systemic, intravenous delivery potential. Mike brings a wealth of experience to Theolytics " said Charlotte Casebourne Stock, Chief Executive Officer of Theolytics. "His track record across all stages of drug development will be invaluable as we progress our lead program into the clinic; I look forward to working closely with him to support the compan
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Liver Cirrhosis Pipeline Insights, 2024: Featuring 45+ Companies and 50+ Pipeline Drugs, Including Elafibranor (Ipsen), Volixibat (Mirum Pharmaceuticals), and PVT201 (Parvus Therapeutics) [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value [Seeking Alpha]Seeking Alpha
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $48.00 price target on the stock.MarketBeat
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
MIRM
Earnings
- 11/2/23 - Beat
MIRM
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- MIRM's page on the SEC website